2. Kerr M., Bray B., Medcalf J. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol. Dial. Transplant. 2012;27(Suppl. 3): iii73–80. Doi: 10.1093/ndt/gfs269.

3. Мыльников М. «VADEMECUM»., разд. Мединдустрия. («Нефро-Лига» предложила Правительству РФ проиндексировать тарифы на диализ на 40–70%). 24.03.2022. https://vademec.ru/news/2022/03/24/ nefro-liga-predlozhila-pravitelstvu-rf-proindeksirovat-tarify-na-dializ- na-40-70. [Mylnikov M. "VADEMECUM", sec. Medical industry. (Nefro-Liga proposed to the Government of the Russian Federation to index tariffs for dialysis by 40–70%). 03/24/2022.

4. U.S. Renal Data System: USRDS 2014 Annual Data Report, 2014.

5. Grantham J.J., Torres V.E., Chapman A.B., et al. CRISP Investigators. Volume progression in polycystic kidney disease. N. Engl. J. Med. 2006; 354(20):2122–30. Doi.org/10.1056/NEJMoa054341 PMid:16707749.

6. Echevers Y.M., Toapanta N., Pérez N.N. Survival of patients ≥70 years with advanced chronic kidney disease: Dialysis vs. conservative care. Nefrologia: publicacion oficial de la Sociedad Esp. Nefrol. 2016;36(3). Doi: 10.1016/ j.nefro.2015.11.006.

7. Helal I. Autosomal dominant polycystic kidney disease: new insights into treatment. Saudi J. Kidney Dis. Transpl. 2013;24(2):230–34. Doi. org/10.4103/1319-2442.109561 PMid:23538343.

8. Binsaleh S., et. al. Comparison of laparoscopic and open nephrectomy for adult polycystic kidney disease: operative challenges and technique. Canad. J. Urol. 2006;6(13):3340–45.

9. Rim H., Jung G.S., Jung Y.S. Transcatheter arterial embolization using ethanol in a dialysis patient for contracting enlarged polycystic kidneys. Korean J. Radiol. 2010;11:574–78. Doi: 10.3348/kjr.2010.11.5.574.

10. ВОЗ: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10- causes-of-death 09.12.2020. WHO https://www.who.int/ru/news-room/ fact-sheets/detail/the-top-10-causes-of-death 09.12.2020.

11. Хроническая болезнь почек (ХБП). Клинические рекомендации Минздрава России. 2021. (Электронный ресурс.) URL: https://www.rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf (дата обращения: 07.04.2022).

12. 1Андрусев А.М., Томилина Н.А., Перегудова Н.Г., Шинкарев М.Б. Заместительная почечная терапия хронической болезни почек 5-й стадии в Российской Федерации 2015–2019 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества. Нефрология и диализ. 2021;23(3):255– 329. Doi: 10.28996/2618-9801-2021-3-255-329. [Andrusev A.M., Tomilina N.A., Peregudova N.G., Shinkarev M.B. Kidney replacement therapy for end Stage Kidney Disease in Russian Federation, 2015–2019. Russian National Kidney Replacement Therapy Registry Report of Russian Public Organization of Nephrologists “Russian Dialysis Society”. Nephrol. Dial. 2021;23(3):255–329. Doi: 10.28996/2618-9801-2021-3-255-329.

13. Чугунова О.Л., Черкасова С.В., Туманова Е.Л. Поликистозная болезнь почек у новорожденных и детей раннего возраста: проблемы диагностики, ведения и лечения. Педиатрия. 2015;94(3):88–94. [Chugunova O.L., Cherkasova S.V., Tumanova E.L. Polycystic kidney disease in newborns and young children: problems of diagnosis, management and treatment. Pediatr. 2015;94(3):88–94.

14. Balat A. Tear drops of kidney: a historical overview of Polycystic Kidney Disease. J. Ital. Nefrol. 2016;33(Suppl. 66):33.S66.21. PMID: 26913889.

15. Steiner P. Ueber grosscystische Degeneration der Nieren und der Leber. Deutsche Med. Wocheschr. 1899;25:677–78.

16. Reed B., McFann K., Kimberling W.J., et al. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am. J. Kidney Dis.: Оfficial J. National Kidney Foundat. 2008;52(6):1042–50. https://doi.org/10.1053/j.ajkd.2008.05.015

17. Porath B., Gainullin V.G., Cornec-Le Gall E., et al. Mutations in GANAB, encoding the glucosidase II alpha subunit, cause autosomal-dominant polycystic kidney and liver disease. Am. J. Human. Genet. 2016;98(6):1193–207. Doi: 10.1016/j.ajhg.2016.05.004.

18. Ars E., Bernis C., Fraga G. Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 2014; 29(Suppl. 4):iv95–105. Doi: 10.1093/ndt/gfu186.

19. Руденко Т.Е., Бобкова И.Н., Ставровская Е.В. Современные подходы к консервативной терапии поликистозной болезни почек. Тер. архив. 2019;91(6):116–23. Doi: 10.26442/00403660.2019.06.000299.

20. Reiterová J.; Tesaˇr V. Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment. Int. J. Mol. Sci. 2022;23:3317. https:// doi.org/10.3390/ijms23063317

21. Волынец Л. И., Нарезкин Д. В., Толкачев А. Н. Поликистоз почек: современное состояние проблемы. Вестник Смоленской государственной медицинской академии. Клин. медицина. УДК: 616.61-006.31.

22. Horie S., Mochizuki T., Muto S., et al. Evidence-based clinical practice guidelines for polycystic kidney disease 2014. Clin. Exp. Nephrol. 2016;20(4):493–509. https://doi.org/10.1007/s10157-015-1219-7

23. Grantham J.J., Chapman A.B., Torres V.E: Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes. Clin. J. Am. Soc. Nephrol. 2006;1:148–57.

24. Chapman A.B., Bost J.E., Torres V.E., et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol 2012;7:479–86.

25. Hayne Cho Park, Yeji Hong, Jeong-Heum Yeon, et al. Mayo imagingclassification is a good predictor of rapid progress among Korean patients with autosomal dominant polycystic kidney disease: results from the KNOW-CKD study. Kidney Res. Clin. Pract. 2022;41(4):432–41. Published online: March 3, 2022. Doi: https://doi.org/10.23876/j.krcp.21.261.

26. Rosenberg S., Virmani S., Klarman Sh., et al. Mayo Imaging Classification May Be Useful in Determining the Need for Nephrectomy in ADPKD. Kidney360 February. 2021;2(2):325–30. Doi: https://doi.org/10.34067/ KID.0003902020.

27. Irazabal M.V., Rangel L.J. Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials. JASN. 2015;26(1):160–72. Doi: https://doi.org/10.1681/ ASN.2013101138.

28. Tangri N., Hougen I., Alam A. Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Can. J. Kidney Health Dis. 2017;4:2054358117693355. Doi: 10.1177/2054358117693355. eCollection 2017.

29. Jones B.E., Mkhaimer Y.G., Rangel L.J. Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease. Kidney 360. 2022;3:465–76. Doi: https://doi.org/10.34067/KID.0004292021.

30. Torres V.E., Abebe K., Chapman, et al. Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease. N. Engl. J. Med. 2014;371:2267–76.

31. Супрунович К.С. Аутосомно-доминантная поликистозная болезнь почек:

32. Woodhead J.L., Pellegrini L., Shoda L.K.M., Howell B.A. Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease Using Quantitative Systems Toxicology Modeling. Pharm. Res. 2020;37(2):24. Doi: 10.1007/s11095-019-2726-0.

33. Meijer E., Drenth J.P., d’Agnolo, et al. Rationale and design of the DIPAK1 study: A randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 2014;63(3):446–55. Doi: 10.1053/ j.ajkd.2013.10.011.

34. Serra A.L., Poster D., Kistler A.D., et al. Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease. N. Engl. J. Med. 2010;363(9):820–9. Doi: 10.1056/NEJMoa0907419.

35. The National Library of Medicine (NLM). ClinicalTrials.gov. https://clinicaltrials.gov.

36. Perrone R.D., Abebe K.Z., Watnick T.J., et al. Primary results of the randomized trial of metformin administration in polycystic kideny disease (TAME PKD). Kidney Int. 2021;100(3):684–96. Doi: 10.1016/j.kint.2021.06.013.

37. Chediak A.E., Degheili J.A., Khauli R.B. Genitourinary Interventions in Autosomal Dominant Polycystic Kidney Disease: Clinical Recommendations for Urologic and Transplant Surgeons. Exp. Clin. Transplant. 2021;19(2):95–103. Doi: 10.6002/ect.2020.0292.

38. Comelis F., Couzi L., Le Bras Y., et al. Embolization of polycystic kidneys as an alternative to nephrectomy before renal transplantation: a pilot study. Am. J. Transplant. 2010;10(10):2363–69. http://dx.doi.org/10.1111/ j.1600-6143.2010.03251.x PMid:21143393.

39. Sallee V.I., Rafat C., Zahar J.R., et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2009;4(7):1183–89. http://dx.doi.org/10.2215/ CJN.01870309

40. Lahiri S.A., Halff G.A., Speeg K.V., Esterl R.M. In-111 WBC scan localizes infected hepatic cysts and confirms their complete resection in adult polycystic kidney disease. Clin. Nucl. Med. 1998;23(l):33–4. http://dx.doi.org/10.1097/00003072-199801000-00010 PMid:9442963

41. Ishikawa I., Saito Y., Asaka V.I., et al. Twenty-year follow-up of acquired renal cystic disease. Clin. Nephrol. 2003;59(3):153–9. http://dx.doi.org/10.5414/ CNP59153 PMid:12653256

42. Лубенников А.Е., Нефрэктомия у больных с терминальной стадией хронической почечной недостаточности. Дисс. док. мед. наук. М., 2021.

43. Amesur P., Castronuovo J.J., Chandramouly B. Infected cyst localization with gallium SPECT imaging in polycystic kidney disease. Clin. Nucl. Med. 1988;13(l):35–7. http://dx.doi.org/10.1097/00003072-198801000-00010 PMid:3258216

44. Dang J., Knebelmann B., Charlier C. FC 010 4-Week Antibiotic Therapy Prevents Recurrent Renal Cyst Infections in Autosomal Dominant Polycystic Kidney Disease. Nephrol. Dial. Transplant. 2021;36(Suppl. 1). Doi: 10.1093/ndt/gfab125.003.

45. Suwabe T. Cyst infection in autosomal dominant polycystic kidney disease: our experience at Toranomon Hospital and future issues. Clin. Exp. Nephrol. 2020;24:748–61. https://doi.org/10.1007/s10157-020-01928-2

46. Kazimirov V.G., Butrin S.V., Sapozhnikov A.D. Kidney transplantation in patients withautosomaldominantpolycystickidneydisease. Volgograd: Gosudarstvennoye uchrezhdeniye «Izdatel'», 2003. 112 p. Russian (Казимиров В.Г., Бутрин С.В., Сапожников А.Д. Трансплантация почки у больных с аутосомно-доминантным поликистозом почек. Волгоград: Государственное учреждение «Издатель», 2003. 112 с.).

47. Veroux M. и др. Change in kidney volume after kidney transplantation in patients with autosomal polycystic kidney disease. PloS one. 2018;12(13):e0209332.

48. Bennett A.H., Lazarus J.M. Bilateral nephrectomy performed on an emergency basis for life-threatening malignant hypertension. Surg. Gynecol. Obstet. 1973;137(3): 451–52.

49. Martin A.D., Mekeel K.L., Castle E.P., et al. Laparoscopic bilateral native nephrectomies with simultaneous kidney transplantation. BJU. Int. 2012;110(11 Pt. C):E1003–7. http://dx.doi.Org/10.llll/j.1464-410X.2012.11379.x.

50. Kirkman M.A., van Dellen D., Mehra S., et al. Native nephrectomy for autosomal dominant polycystic kidney disease: before or after kidney transplantation? BJU. Int. 2011;108(4):590–94. http://dx.doi.Org/10.llll/ j.1464-410X.2010.09938.x PMid:21166760

51. Argyrou C., Moris D., Vernadakis S. Tailoring the ‘perfect fit’ for renal transplant recipients with end-stage polycystic kidney disease: Indications and timing of native nephrectomy. In Vivo 31:307–312, 2017. https://doi.org/10.21873/invivo.11060

52. Brazda E., Ofner D., Riedmann B., et al. The effect of nephrectomy on the outcome of renal transplantation in patients with polycystic kidney disease. Ann. Transplant. 1996;l(2):15–8

53. Elashry O.M., Nakada S.Y., Wolf J.S., et al. Laparoscopy for adult polycystic kidney disease: a promising alternative. Am. J. Kidney Dis. 1996;27(2): 224–33. http://dx.doi.org/10.1016/50272-6386(96)90545-4

54. Jenkins M.A., Crane J.J., Munch L.C. Bilateral hand-assistedlaparoscopic nephrectomy for autosomal dominant polycystic kidney disease using a single midline HandPort incision. J. Urol. 2002;59(l):32–6. http://dx.doi.org/10.1016/50090-4295(01)01461-3

55. Gill I.S., Kaouk J.H., Hobart M.G., et al. Laparoscopic bilateral synchronous nephrectomy for autosomal dominant polycystic kidney disease: the initial experience. J. Urol. 2001;165(4):1093–98. http://dx.doi.org/10.1016/ S0022-5347(05)66435-X

56. Lipke M.C., Bargman V., Milgrom M., Sundaram C.P. Limitations of laparoscopy for bilateral nephrectomy for autosomal dominant polycystic kidney disease. J. Urol. 2007;177(2):627–31. http://dx.doi.org/10.1016/ j.juro.2006.09.026 PMid:17222647

57. Whitten M.G., Van Der W.W., Belnap L. A novel approach to bilateralhand- assisted laparoscopic nephrectomy for autosomal dominant polycystic kidneydisease. Surg. Endoscop. Other Interv. Techniq. 2006;4(20):679–84.

58. Neeff H.P., Pisarski P., Tittelbach-Helmrich D., et al. One hundred consecutive kidney transplantations with simultaneous ipsilateral nephrectomy in patients with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 2013;28(2):466–71. http:// dx.doi.org/10.1093/ndt/gfsll8 PMid:23042709

59. Sulikowski T., Tejchman K., Zietek Z., et al. Experience with autosomal dominant polycystic kidney disease in patients before and after renal transplantation: a 7-year observation. Transplant. Proc. 2009;41(l):177–80. http:// dx.doi.org/10.1016/j.transproceed.2008.10.034 PMid:19249508

60. Mendez R., Mendez R.G., Payne J.E., Berne T.V. Renal transplantation. In adult patients with end stage polycystic kidney disease. J. Urol. 1975;5(l):26–7. http://dx.doi.org/10.1016/0090-4295(75)90295-2

61. Kramer A., Sausville J., Haririan A., et al. Simultaneous bilateral native nephrectomy and living donor renal transplantation are successful for polycystic kidney disease: the University of Maryland experience. J. Urol. 2009;181(2):724–28. http:// dx.doi.org/10.1016/ j.juro.2008.10.008.

62. Tyson M.D., Wisenbaugh E.S., Andrews P.E., et al. Simultaneous kidney transplantation and bilateral native nephrectomy for polycystic kidney disease. J. Urol. 2013;190(6):2170–74. http://dx.doi.org/10.1016/j.juro.2013.05.057 PMid:23727414

63. Tabibi A., Simforoosh N., Abadpour P., et al. Concomitant nephrectomy of massively enlarged kidneys and renal transplantation in autosomal dominant polycystic kidney disease. Transplant. Proc. 2005;37(7):2939–40. http:// dx.doi.org/10.1016/j.transproceed.2005.07.053.

64. Ronsin Ch., Chaba A.., Suchanek O. Incidence, Risk Factors and Outcomes of Kidney and Liver Cyst Infection in Kidney Transplant Recipient With ADPKD. Kidney Int. Rep. 2022;7:867–75. https://doi.org/10.1016/j.ekir.2022.01.1062

65. Oguro M., Suwabe T., Ubara Y. Repetitive Refractory Renal Cyst Infection in Autosomal Dominant Polycystic Kidney Disease for which Renal Transcatheter Arterial Embolization Was Effective in Preventing Recurrence. Intern. Med. 2021;60(20):3261–65. Doi: 10.2169/internalmedicine.6974-20.